ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Infinity Pharmaceuticals, Inc." (INFI) Report Updated: Sep 26, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Infinity Pharmaceuticals, Inc." (INFI)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: ARIA,DMPI,MNOV,MDVN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Infinity Pharmaceuticals, Inc."© quotemedia

Company Profile

Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; DYNAMO+R that is in Phase III randomized study to evaluate IPI-145 dosed at 25 mg in combination with rituximab, a monoclonal antibody treatment; and DUO, which is in randomized Phase III monotherapy study evaluating IPI-145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). It is also conducting a Phase Ib trial of IPI-145 in combination with obinutuzumab, a monoclonal antibody treatment in CLL patients; a Phase Ib/II clinical study of IPI-145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma; and an ongoing Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies. The company has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI-145 in oncology; and development and license agreement with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.